QuanBio is a groundbreaking company at the forefront of cardiovascular health innovation. Co-founded by Astrid Androsch and Dr. Vlad Friedman, a New York Presbyterian cardiologist, the company aims to address a significant gap in the healthcare system: early detection of cardiovascular disease. Cardiovascular issues, often referred to as silent killers, are typically diagnosed too late, when arteries are often up to 95% blocked. QuanBio’s mission is to change that narrative by providing an affordable, accessible, and innovative solution.
Transforming Detection with AI and Science
QuanBio has developed a non-invasive medical platform that uses Photoplethysmography (PPG) to measure arterial stiffness—a key indicator of cardiovascular health. The non-invasive medical device and software leverages machine learning to rapidly analyze arterial stiffness. Their AI algorithms are specifically engineered to adapt and learn from complex patterns in cardiovascular data, providing 25 biomarkers to gauge vascular health. This innovation enables doctors to assess patients’ cardiovascular health in real-time, at point of care, paving the way for early interventions and personalized medicine.
“Our goal is not just rapid detection but accessibility. We aim to address cardiovascular-related inequities, by serving as an affordable tool for screening of vascular health.” said Androsch. This transformative technology is expected to have a profound impact on underserved communities, particularly those in rural areas where access to healthcare is limited.
Thriving in New Jersey’s Innovation Ecosystem
In its pursuit of an ideal environment to grow, QuanBio relocated from Atlanta, Georgia to the New Jersey Innovation Institute’s (NJII) Incubator in Newark, New Jersey, drawn by the robust technology and healthcare ecosystem fostered by NJII and other innovation leaders. “From the moment we began negotiations to move here, we’ve experienced incredible support,” Androsch shared. QuanBio has benefited from connections to investors, partnerships with healthcare systems, and access to top-tier talent through programs like NJII’s internship initiatives.
The company’s collaboration with Rutgers University and its partnerships with esteemed researchers such as Dr. Partho Sengupta have further cemented their position as leaders in cardiovascular innovation.
Overcoming Challenges and Words of Wisdom
Like many startups, QuanBio has faced challenges, particularly in securing warm introductions within New Jersey’s tight-knit investment community. The team stressed the importance of networking, never giving up, and being prepared to hear ‘no’ many times before you succeed, which are mantras they have followed to their current success.
Reflecting on her journey, Androsch offered advice for those starting their entrepreneurial paths:
- Embrace Complexity: “Never underestimate the complexity of what you’re embarking on.”
- Follow Your Passion: “Listen to others but trust your vision even when others doubt you.”
- Stay Resilient: “If I’d listened to every person who told me what we’re doing wasn’t needed, we wouldn’t be here today.”
Looking Ahead
QuanBio is currently preparing for FDA submission and aiming for broader market adoption as they advance their innovation toward market entry. The team remains committed to its vision: redefining cardiovascular care through innovation, accessibility, and prevention. With the support of partners like NJII and the New Jersey healthcare ecosystem, QuanBio is poised to revolutionize cardiovascular health, saving countless lives along the way.
For more updates on QuanBio’s journey, visit their website